Neurotez Inc. on NetCapital

Neurotez Inc. is developing a drug to treat Leptin deficiency in Alzheimer’s patients.

Raise to date: $132,738

Reporting Date: 04/05/2020

Key Stats

Minimum Raise


Maximum Raise


Likelihood of Max Unlikely
Start Date


Stop Date


Days Remaining


Security Type

Common Stock

Investment Minimum


Deal Type

Deal to Watch

Investment Summary



# of Investors

Not Known

% of Minimum Raised


% of Maximum Raised


Dollars Per Day to Reach Max


DPD* Committed


DPD* Category


DPD* All Companies


Kingscrowd Momentum


Total Dollars Raised


Weekly Commitments ($)
Aggregate Commitments ($)

SEC Filing Data from Kingscrowd

Neurotez, with a post-money valuation of $22.5 million, is raising funds on NetCapital. The company is developing a hormone replacement therapy named Memtin to treat Leptin deficiency in Alzheimer’s patients. The drug will help slow down the cognitive decline in Alzheimer’s patients and other forms of dementia. Neurotez is led by Nikolaos Tezapsidis as the President and CEO, and Wes Ashford as the Chief Medical Officer. The company has already raised $4.5 million in funding from the National Institute of Health, IRS, and New Jersey Commission of Science and Technology. The current crowdfunding round has a minimum goal of $10,000 and a maximum goal of $500,000, and the proceeds will be used for the various studies, clinical trials, manufacturing, personnel costs, and debt repayment. Neurotez has already received many rewards and recognitions and is backed by an excellent team of experts.